Abstract: The present study aims to determine the risk of early secondary nasal revisions in patients with complete unilateral and bilateral cleft lip and palate (U/BCLP) treated with and without nasoalveolar molding (NAM) and examine the associated costs of care. A retrospective cohort study from 1990 to 1999 was performed comparing the risk of early secondary nasal revision surgery in patients with a CLP treated with NAM and surgery (cleft lip repair and primary surgical nasal reconstruction) versus surgery alone in a private practice and tertiary level clinic. The NAM treatment group consisted of 172 patients with UCLP and 71 patients with BCLP, whereas the non-NAM-prepared group consisted of 28 patients with UCLP and 5 with BCLP. The risk of secondary nasal revision for patients with UCLP was 3% in the NAM group and 21% in the non-NAM group. The risk of secondary nasal revision for patients with BCLP was 7% in the NAM group compared with 40% in the non-NAM group. Using multicenter averages, the non-NAM revision rates were calculated at 37.8% and 48.5% for U/BCLP, respectively. Applying these risks of revision, NAM treatment led to an estimated savings of between $491 and $4893 depending on the type of cleft. In conclusion, NAM can reduce the number of early secondary nasal revision surgeries and, therefore, reduce the overall cost of care.
T he nasal deformities associated with unilateral cleft lip and palate (UCLP) and bilateral cleft lip and palate (BCLP) are complex. In the patient with UCLP, the nostril base is wide on the cleft side; the affected lower lateral nasal cartilage is displaced laterally, inferiorly, and posteriorly resulting in a depressed nasal dome, an oblique columella, and an overhanging nostril apex (ie, soft triangle). If there is a cleft of the palate, the nasal septum deviates to the noncleft side with an associated shift of the nasal base. 1 Other factors associated with UCLP nasal deformity include hypoplasia of the lesser alveolar segment as well as a deficiency of maxillary bone. 2, 3 The bilateral cleft nasal deformity typically arises from a procumbent and/or rotated premaxilla (Fig. 1) . The alar base width is significantly increased bilaterally, and the lip segments are widely separated. The flattened nasal tip is tethered directly to the prolabium by a severely deficient or absent columella. The lower lateral alar cartilages are flared and concave where they should be convex. The greatest challenge for aesthetic reconstruction in bilateral clefts is the absent or deficient columella. Although the septum is usually deviated in bilateral clefts, it is less of an issue compared to unilateral clefts. 4 Presurgical nasoalveolar molding (NAM) has been posited to play a significant role in reducing the magnitude of the cleft lip and associated nasal and dentoalveolar deformities (Fig. 1) . Specifically, it has been argued that NAM acts as an inductive mechanism to stimulate the activity of immature nasal chondroblasts, producing an interstitial expansion that is associated with improvements in nasal morphology. 5 Furthermore, active molding and repositioning of the nasal cartilages is based on the same principles as neonatal auricular cartilage manipulation. 6 Both take advantage of the plasticity of cartilage in the newborn infant, potentially caused by the high levels of circulating hyaluronic acid present for several weeks after birth.
Prior research suggests that NAM may improve a number of important features including the nasal cartilage deformity, nasal asymmetry, and may also stretch the nasal mucosal lining and achieve nonsurgical elongation of the columella. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The combination of nasal and alveolar molding has resulted in measurable long-term benefits to the patients, including improved nasal shape and symmetry. [18] [19] [20] [21] [22] The aim of the present retrospective cohort study was to investigate the effect of NAM on the risk of early secondary nasal revision rates as well as the cost of care. It is hypothesized that for both UCLP and BCLP the risk of early secondary nasal revision will be lower in NAM-prepared patients compared with non-NAMprepared patients. It is further hypothesized that for both patients with UCLP and BCLP, NAM preparation will be associated with a lower cost of care.
MATERIALS AND METHODS

Presurgical Nasoalveolar Molding Therapy and Risk of Early Nasal Revision Surgery
After obtaining institutional review board approval for the present retrospective cohort study, a chart review was performed on all of the patients with nonsyndromic complete UCLP or BCLP who had primary lip and nasal reconstruction performed by the same surgeon (C.B.C.) between 1990 and 1999. Data were abstracted on cleft type (UCLP vs BLCP), preoperative NAM therapy status (NAM vs no NAM), and whether early secondary revision nasal surgery was performed (early revision surgery vs no early revision surgery). All of the patients who received preoperative NAM therapy had it performed by the same orthodontist (the senior author; B.H.G.). Patients who did not have preoperative NAM therapy either elected not to undergo NAM treatment or presented at an age (>3 months) that was too late to initiate the treatment. All of the patients with complete UCLP and BCLP were considered to be eligible for NAM therapy unless the patient presented at later than 3 months of age. Dentoalveolar width and degree of nasal deformity were not determining factors in the decision to undergo or forgo NAM therapy.
Nasal revision surgery was defined as ''early'' when performed in patients older than 5 but younger than 14 years of age. (No patient was considered for revision nasal surgery before 5 years of age.) All of the patients were assessed by the treating surgeon for the need for early secondary nasal revision surgery. The surgeon's recommendation for such surgery took into consideration the degree of residual deformity and stigmata of the cleft nose and the need to address those residual deformities before a child's increased social interaction, and family and/or patient concern. Secondary cleft nasal deformities that were recommended for revision included a depressed nasal ala and soft triangle, under projected nasal tip, laterally and inferiorly displaced nasal ala, and nasal aperture asymmetries. When indicated, early secondary nasal revision surgery was performed in patients 5 to 14 years of age. Only patients with complete data were included in analyses.
Cross-tabulation was performed separately for UCLP and BCLP based on NAM treatment status and early nasal revision surgery status. In patients with UCLP, x 2 is used to estimate the effect of NAM treatment on the risk of early nasal revision surgery. Because of the small sample size, a two-tailed Fisher exact test was used to compare BCLP groups.
Cost Analyses
For cost analyses, the overall average costs for patients who received unilateral cleft lip repair surgery, bilateral cleft lip repair surgery, and secondary cleft nasal reconstruction surgery were obtained from the hospital billing department and the overall average costs of NAM therapy for UCLP and BCLP were obtained from the Division of Craniofacial Orthodontics. To calculate whether preoperative NAM therapy resulted in cost savings, the cost of surgery among NAM-prepared and non-NAM-prepared patients is calculated, and the cost of revision surgery is multiplied by the likelihood of revision. Then the cost of NAM therapy for the NAM-prepared group is added. This approach estimates the expected cost per patient in both the NAM therapy and non-NAM therapy streams. There are 3 main variables that affect cost in these calculations: the cost of NAM, the likelihood of revision surgery, and the cost of revision surgery. Because the likelihood of revision can vary between sites and depends on patients, estimates of cost depends heavily on the ability to estimate the likelihood of revision. To estimate this risk, 2 methods are used. First, the cost calculated using the risks derived from the present study is provided. Second, to provide a global average, the literature was reviewed to estimate this risk across centers and studies. Specifically, PubMed and Google Scholar articles were searched using the terms ''Cleft'' and ''Revision'' surgery. For published studies with sufficient information, the reported data were used to calculate a ''weighted-average'' risk of secondary revision surgery for both UCLP and BCLP. Specifically, the risk is weighted by the sample size before it is summed and divided by the overall number of patients reported. This average differs from a standard average in that it provides more weight to larger studies and less weight to smaller studies wherein the variability is much larger. Studyspecific averages are provided and 95% confidence intervals, shown in graphical analyses using bars, were calculated using the Wilson method. 23 
RESULTS
Presurgical Nasoalveolar Molding Therapy and Risk of Early Nasal Revision Surgery
A total of 276 consecutively enrolled patients with isolated nonsyndromic complete UCLP and BCLP met the inclusion criteria. Two hundred patients had a diagnosis of UCLP and 76 had BCLP. Two hundred forty-three patients had received presurgical NAM preparation, whereas 33 did not. Among the patients with UCLP, 86% had presurgical NAM preparation (n ¼ 172) and 28% did not (n ¼ 28). In the group with BLCP, 93% (71/76) had presurgical NAM therapy.
Of the 172 patients with UCLP who were treated with NAM and primary nasal reconstruction, 5 patients (3%) underwent early secondary nasal revision surgery. Of the 28 patients with UCLP who did not receive NAM, 6 patients (21%) underwent an early nasal revision. There was a significant difference between the proportion of UCLP patients with NAM and without NAM who underwent early secondary nasal revisions (x 2 ¼ 15.9, P < 0.001) ( Table 1) . Similarly, 5 of 71 (7%) patients with BCLP who were treated with NAM underwent an early secondary revision compared with 2 of 5 (40%) patients with BCLP not treated with NAM. Although substantial, due in part to small sample sizes, this relationship was not significant (Fisher exact test ¼ 0.064) ( Table 2) . 
Patel et al
A multicenter average risk was derived from 13 studies identified in the literature from 1993 to 2013. These 13 studies had a total sample size of 2287 with 1854 and 433 patients with U/BCLP, respectively. Among UCLP patients, estimated risk of secondary revision surgery ranged from 21% to 87%, and averaged 37.8%, (95% confidence interval ¼ 35.6, 40.0); among BCLP patients, the risk ranged from 34% to 88%, with an average of 48.5% (43.8%, 53.2%). The average risk of secondary nasal revision surgery among NAM-prepared patients with UCLP in the present study (3%) is also low in comparison with the multicenter average revision risk (Fig. 2) for non-NAM-prepared patients with UCLP (37.8%) derived from 10 studies in the literature (P < 0.001). A similar pattern was evident among patients with BCLP; the average risk of secondary nasal revision surgery among NAM-prepared patients in the present study was 7% compared with the 48.5% multicenter average risk derived from 6 studies among non-NAMprepared patients (P < 0.001).
Cost Analysis
The average cost of a unilateral cleft lip repair and bilateral cleft lip repair with associated hospital fees is $30 380.38 and $41 302.53, respectively ( Table 3 ). The addition of NAM before primary surgical repair of a unilateral cleft lip and a bilateral cleft lip increases these costs by $4500.00 and $6500.00, respectively. The average cost of a secondary nasal reconstruction and associated hospital fees is $26 945.11. Using secondary revision rates derived from Tables 1 and 2 above and the procedure costs at a single institution, it is estimated that the average cost of care for a patient with a NAM-prepared UCLP is [30 380 .38 þ 4500.00 þ (0.029 Â 26 945.11) ¼ ] $35 664, whereas the average for a patient with a non-NAM prepared UCLP is $36 154. Nasoalveolar molding preparation saves around $491 per patient with UCLP and approximately $2381 per patient with BLCP.
Using average risks calculated above (Fig. 2) , the cost of care for non-NAM-prepared UCLP patients (noting the risk of revision was estimated at 37.8%) is on average $40 557 compared with $35 664 for NAM-prepared patients, a savings of $4893 per patient. For patients with BCLP (with an estimated risk of revision at 48.5%), the costs are higher ($54 371 and $49 700, respectively) but the savings are similar ($4671).
To calculate the total cost savings among our cohort of study participants, per-patient savings are multiplied by the number of patients in the study. In the present study, 172 patients with UCLP and 71 patients with BCLP underwent NAM; using the study-specific (conservative) cost estimates shown above, this represents a total estimated savings at a single institution of $84 394 among patients with UCLP and $169 016 among patients with BCLP. Using the risk of revision derived from the literature, the savings would be closer to $841 596 and $331 641 for U/BCLP, respectively.
DISCUSSION
Preoperative NAM treatment was found to be associated with a lower average risk of secondary nasal revision surgery. This pattern was evident when comparing the revision risk among patients with UCLP treated with and without NAM (3% vs 21%) as well as among patients with BCLP (7% vs 40%). Similarly, the average risks of secondary nasal revisions among patients treated with NAM were significantly lower than the multicenter average risks of revision derived from the literature for non-NAM-prepared patients with UCLP (37.8%, P < 0.001) and BCLP (48.5% P < 0.001). 
FIGURE 2.
Percentage of patients with secondary nasal revision surgery by cleft type in published studies, 1993-2013. Studies included were identified in the literature using search terms ''cleft'' and ''revision'' on PubMed and Google Scholar. Studies included in analysis reported sufficient data for calculating a risk of revision. Studies that referred to data provided in another study cited were excluded. 95% confidence intervals, calculated using the Wilson method, are provided using error bars: bars that are closer to the mean generally have larger sample sizes. Non-nasoalveolar molding-prepared sample-weighted means are provided, with accompanying 95% confidence interval. Further using either average risks of secondary nasal revision surgery generated from the present study or from the literature, NAM preparation results in substantial cost savings (between $491 and $4893 per patient), even after accounting for the expense of NAM preparation. These findings suggest a potential role of NAM in reducing the risk of secondary nasal revisions, the burden of that care to the patient and society, and the associated costs.
It is important to note that there are limitations to our work. For example, a selection bias could exist wherein patients with greater initial cleft severity did not receive NAM treatment. NAM therapy is, however, offered to all of the patients who present to our institution with complete UCLP and BLCP. The decision to initiate NAM is not based on cleft severity, but instead based on family factors (eg, distance to travel) and time of initial presentation (eg, patient must present by 3 months of age). It is possible although that unobserved factors affect either the decision to use NAM therapy or the age of initial presentation. We are unaware of any reason why this may be the case; however, if such issues are present, then we may expect differences to emerge between the revision rate in our study and previously reported revision rates. The revision rate in non-NAM treated patients in our study was, however, not significantly different from the revision rate reported in other studies. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] In addition, analyses were limited by a small sample size in non-NAM group, especially among patients with BCLP. To account for this fact, we provided analyses using meta-analytic averages, which show even stronger support for a lowered risk of revision among NAM-prepared patients. Finally, our cost analysis is limited because we only considered whether or not patients underwent revision surgery. This binary end point does not include factors such as the financial costs incurred by some patients who undergo multiple revision surgeries; our cost estimates, therefore, are likely conservative.
Outside our center, which offers financial assistance, the cost of NAM preparation, which we calculated as $4500 and $6500 for U/BCLP, respectively, is likely to be a barrier for many patient/ families because many insurance providers do not cover or only partially cover NAM therapy. 37 These analyses suggest that having presurgical NAM preparation as a universally covered benefit could lead to an overall cost savings of between $491 and $4893, even after accounting for the cost of NAM. Such a shift in policy may ultimately improve outcomes while reducing costs.
In our experience, combining NAM molding with primary nasal reconstruction resulted in a 3% revision rate for UCLP and 7% for BCLP as compared with 21% rate for UCLP and 40% BLCP in our non-NAM population. The long-term retention of nasal symmetry (up to 12 years) and nasal tip projection 21 may be responsible for the relatively low rate of early secondary surgical revisions. In any case, lowering the risk of secondary nasal revision surgery has serious fiscal and emotional consequences. Although we found that NAM preparation provided substantial savings over traditional methods, further analyses are required to examine the emotional, social, or psychological consequences of this reduction.
When we performed a cost analysis reviewing the total cost of performing an early secondary nasal revision surgery, we found that in the non-NAM control, the cost of secondary nasal revision surgery resulted in a 4.8% increase in the total cost of care. Despite the subjectivity involved in the decision to perform early secondary nasal revision surgery, our criteria was the same for both the NAM and non-NAM groups and was determined by the senior surgeon (C.B.C.) and agreement by the families. Therefore, our data demonstrate that the results of presurgical NAM can reduce the need for early secondary nasal revision surgery and consequently reduce the overall cost and surgery-associated burden of care for this patient population. The overall cost savings between the NAM and non-NAM as a group is small; however, potentially reducing the number of surgeries for a similar reconstructive outcome is invaluable in terms of reducing the morbidities and emotional stress associated with anesthesia and surgery for a child. For the individual patient who undergoes NAM and, therefore, does not require secondary surgery, there is, however, a cost savings of $26 945.11. By reducing the number of operations and cost of overall care, NAM can reduce the burden of care to the family/ patient and the burden of medical costs to society as a whole.
